文献速递免疫规划慢病防控与筛查

单中心25年心脏移植患者乙型肝炎疫苗与肺炎球菌疫苗接种经验:COVID-19大流行的影响

A single center's 25-year experience with hepatitis B and pneumoccocal vaccines in heart transplant patients: the impact of the COVID-19 pandemic.
PubMed 文献 · Vaccine · 2025-11-26

该单中心研究纳入1998年1月至2024年1月间接受心脏移植的174例成人患者,评估其乙型肝炎疫苗和肺炎球菌疫苗接种情况及抗体应答。移植后乙型肝炎疫苗接种率从移植前31.4%升至47.1%(p=0.007),PCV13从5.7%升至37.4%(p<.001)。大流行前后比较,PCV13接种率从11.2%升至36.7%(p<.001),HBV疫苗从40.0%升至45.9%(p=0.326)。作者认为接种率仍不理想,大流行似乎积极影响了肺炎球菌疫苗接种。

要点

  • 心脏移植患者移植后HBV疫苗接种率47.1%,仍不理想。
  • PCV13接种率移植后37.4%,较大流行前明显提升。
  • 大流行后PCV13接种率从11.2%升至36.7%。

核心结论

  • 心脏移植受者疫苗接种率仍不理想,但COVID-19大流行似乎积极影响了肺炎球菌疫苗接种率,反映对呼吸道感染认识提高。
  • 作者认为需要进一步研究探索该人群的临床结局和最佳接种时机。

研究设计与样本

  • 单中心研究,纳入1998年1月至2024年1月期间接受心脏移植的18岁及以上患者。
  • 共评估295例患者,其中174例符合纳入标准。
  • 移植时平均年龄38.8±16.1岁,女性占21.8%。
  • 评估乙型肝炎疫苗接种状态及抗体应答,以及肺炎球菌疫苗接种状态,比较大流行前后接种率变化。

主要发现

  • 乙型肝炎疫苗接种率从移植前31.4%升至移植后47.1%(p=0.007)。
  • 肺炎球菌结合疫苗(PCV13)接种率从移植前5.7%升至移植后37.4%(p<.001)。
  • 大流行前后比较,PCV13接种率从11.2%升至36.7%(p<.001)。
  • 大流行前后比较,HBV疫苗接种率从40.0%升至45.9%(p=0.326)。

局限性

  • 作者指出需要进一步研究探索该人群的临床结局和最佳接种时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although vaccination is known to be of critical importance in solid organ transplant recipients. This study aims to evaluate the vaccination status of heart transplant patients and the changes in vaccination rates following the pandemic. METHODS: Patients aged 18 years or older who underwent heart transplantation between January 1998 and January 2024 were included. Hepatitis B (HBV) vaccination status and antibody responses, as well as vaccination status with pneumococcal vaccine were evaluated. Vaccination rates were analyzed over the years, comparing the pre-pandemic and post-pandemic periods. RESULTS: Among 295 evaluated patients, 174 met the inclusion criteria. The mean age at transplantation was 38.8 ± 16.1 years, and 21.8 % were female. The hepatitis B vaccination rate increased from 31.4 % pre-transplant to 47.1 % post-transplant (p: 0.007). For pneumococcal conjugate vaccine (PCV13), the rate rose from 5.7 % pre-transplant to 37.4 % post-transplant (p < .001). Comparing pandemic periods, PCV13 vaccination increased from 11.2 % to 36.7 % (p < .001), while HBV vaccination increased modestly from 40.0 % to 45.9 % (p: 0.326). CONCLUSION: Vaccination rates among heart transplant recipients remain suboptimal. Nevertheless, the COVID-19 pandemic appears to have positively influenced pneumococcal vaccination uptake, reflecting heightened awareness of respiratory infections. Further research is warranted to explore the clinical outcomes and optimal timing of vaccination in this population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vahabi MM, Ketentzi S, Kahraman Ü, et al. A single center's 25-year experience with hepatitis B and pneumoccocal vaccines in heart transplant patients: the impact of the COVID-19 pandemic. Vaccine. 2025. PMID: 41308248. doi:10.1016/j.vaccine.2025.128023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。